Qiming Venture Partners Announces Fund Closing Totaling US$3.2 Billion

SHANGHAI, July 10, 2022 /PRNewswire/ — Qiming Venture Partners today announced the closing of its latest funds totaling US$3.2 billionincluding USD Fund VIII to US$2.5 billion and the first closing of RMB Fund VII at 4.7 billion RMB (Where 700 million US dollars).

As with previous funds, Fund VIII was oversubscribed and reached its hard cap for limited partner commitments. This increases the capital of the company raised to $9.4 billion through 18 funds.

Committed capital includes lead fund Qiming Venture Partners Fund VIII which focuses on technology and consumer (T&C) investments and early-stage and growth-stage healthcare, and parallel healthcare fund Qiming Venture Partners Fund VIII-HC which invests alongside the main fund (collectively “Fund VIII”).

Fund VIII is led by Managing Partners Duane Kuang, Nisa Leung, William Huand Gary Rieschelwith the full support of the investment and administration teams based in Shanghai, beijing, Shenzhenand hong kong.

Since its inception in 2006, Qiming has demonstrated its ability to generate strong and consistent venture capital returns in China. Qiming has supported more than 480 fast-growing companies, of which more than 70 have achieved unicorn status. A large majority of these companies were at an early stage at the time of the initial investment. Additionally, more than 180 of our portfolio companies have achieved exits through IPOs, M&As, or other means, including Xiaomi, Gan & Lee Pharmaceuticals, Tigermed, Zai LaboratoryCanSino Biologics, APT Medical, Meituan, Bilibili and Roborock.

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leader China venture capital firm with offices in Shanghai, beijingSuzhou, hong kong, Seattle, Boston and the San Francisco Bay Area.

Currently, Qiming Venture Partners manages eleven american dollars funds and seven RMB funds with $9.4 billion in raised capital. Since our inception, we have invested in outstanding early-stage and growth-stage technology and consumer (T&C) and healthcare companies.

Since our inception, we have supported over 480 innovative and fast-growing companies. More than 180 of our portfolio companies have achieved exits through IPOs on NYSE, NASDAQ, HKEX, Shanghai Stock Exchange or Shenzhen Stock Exchange, or through mergers and acquisitions or by other means. There are also over 70 holding companies that have achieved unicorn status.

Many of the companies in our portfolio are the most influential companies in their respective industries today, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE : ZH, SEHK: 2390), Roborock (SHSE: 688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE: 300347, SEHK: 3347), Zai Laboratory (NASDAQ: ZLAB, SEHK: 9688), CanSino Biologics (SEHK: 6185, SHSE: 688185), Schrödinger (NASDAQ: SDGR), APT Medical (SHSE: 688617), New Horizon Health (SEHK: 6606), Venus MedTech (SEHK :2500), Sanyou Medical (SHSE: 688085), AmoyDx (SZSE: 300685), Berry Genomics (SZSE: 000710), SinocellTech (SHSE: 688520), Yuanxin Technology, dMed-Clinipace, Belief BioMed, WeRide, Biren Technology and UBTech among many others.

SOURCEQiming Venture Partners

Comments are closed.